S'abonner

Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study - 21/04/15

Doi : 10.1016/S1473-3099(15)70090-3 
Marcel A Müller, PhD a, Benjamin Meyer, MSc a, Victor M Corman, MD a, b, Malak Al-Masri, BSc f, Abdulhafeez Turkestani, MD g, Daniel Ritz, MSc a, Andrea Sieberg, BSc a, Souhaib Aldabbagh, DVM a, Berend-J Bosch, PhD h, Erik Lattwein, PhD i, Raafat F Alhakeem, MD f, Abdullah M Assiri, MD f, Ali M Albarrak, MD c, Ali M Al-Shangiti, PhD d, Jaffar A Al-Tawfiq, MD j, k, Paul Wikramaratna, PhD l, Abdullah A Alrabeeah, MD e, Christian Drosten, ProfMD a, b, , , Ziad A Memish, ProfMD f, m, ,
a Institute of Virology, University of Bonn Medical Centre, Bonn, Germany 
b German Centre for Infection Research, Partner Site Bonn-Cologne, Bonn, Germany 
c Saudi Center for Disease Control, Riyadh, Saudi Arabia 
d National Health Laboratory, Riyadh, Saudi Arabia 
e King Abdulaziz Medical City & Advisor Royal Court, Riyadh, Saudi Arabia 
f Ministry of Health, Riyadh, Saudi Arabia 
g Makkah Regional Health Affairs, Ministry of Health, Makkah, Saudi Arabia 
h Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands 
i Euroimmun AG, Lübeck, Germany 
j Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia 
k Indiana University School of Medicine, Indianapolis, IN, USA 
l Institute of Evolutionary Biology, University of Edinburgh, Centre for Infection, Immunity and Evolution, Edinburgh, UK 
m Alfaisal University, Riyadh, Saudi Arabia 

* Correspondence to: Prof Ziad A Memish, Ministry of Health, Preventive Medicine, PO Box 54146, Riyadh 11514, Saudi Arabia ** Prof Christian Drosten, Institute of Virology, University of Bonn Medical Centre, Bonn, D-53127, Germany

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Summary

Background

Scientific evidence suggests that dromedary camels are the intermediary host for the Middle East respiratory syndrome coronavirus (MERS-CoV). However, the actual number of infections in people who have had contact with camels is unknown and most index patients cannot recall any such contact. We aimed to do a nationwide serosurvey in Saudi Arabia to establish the prevalence of MERS-CoV antibodies, both in the general population and in populations of individuals who have maximum exposure to camels.

Methods

In the cross-sectional serosurvey, we tested human serum samples obtained from healthy individuals older than 15 years who attended primary health-care centres or participated in a national burden-of-disease study in all 13 provinces of Saudi Arabia. Additionally, we tested serum samples from shepherds and abattoir workers with occupational exposure to camels. Samples were screened by recombinant ELISA and MERS-CoV seropositivity was confirmed by recombinant immunofluorescence and plaque reduction neutralisation tests. We used two-tailed Mann Whitney U exact tests, χ2, and Fisher’s exact tests to analyse the data.

Findings

Between Dec 1, 2012, and Dec 1, 2013, we obtained individual serum samples from 10 009 individuals. Anti-MERS-CoV antibodies were confirmed in 15 (0·15%; 95% CI 0·09–0·24) of 10 009 people in six of the 13 provinces. The mean age of seropositive individuals was significantly younger than that of patients with reported, laboratory-confirmed, primary Middle Eastern respiratory syndrome (43·5 years [SD 17·3] vs 53·8 years [17·5]; p=0·008). Men had a higher antibody prevalence than did women (11 [0·25%] of 4341 vs two [0·05%] of 4378; p=0·028) and antibody prevalence was significantly higher in central versus coastal provinces (14 [0·26%] of 5479 vs one [0·02%] of 4529; p=0·003). Compared with the general population, seroprevalence of MERS-CoV antibodies was significantly increased by 15 times in shepherds (two [2·3%] of 87, p=0·0004) and by 23 times in slaughterhouse workers (five [3·6%] of 140; p<0·0001).

Interpretation

Seroprevalence of MERS-CoV antibodies was significantly higher in camel-exposed individuals than in the general population. By simple multiplication, a projected 44 951 (95% CI 26 971–71 922) individuals older than 15 years might be seropositive for MERS-CoV in Saudi Arabia. These individuals might be the source of infection for patients with confirmed MERS who had no previous exposure to camels.

Funding

European Union, German Centre for Infection Research, Federal Ministry of Education and Research, German Research Council, and Ministry of Health of Saudi Arabia.

Le texte complet de cet article est disponible en PDF.

Plan


© 2015  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 15 - N° 5

P. 559-564 - mai 2015 Retour au numéro
Article précédent Article précédent
  • Diagnostic accuracy of loop-mediated isothermal amplification as a near-patient test for meningococcal disease in children: an observational cohort study
  • Thomas W Bourke, James P McKenna, Peter V Coyle, Michael D Shields, Derek J Fairley
| Article suivant Article suivant
  • Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis
  • Mélanie Drolet, Élodie Bénard, Marie-Claude Boily, Hammad Ali, Louise Baandrup, Heidi Bauer, Simon Beddows, Jacques Brisson, Julia M L Brotherton, Teresa Cummings, Basil Donovan, Christopher K Fairley, Elaine W Flagg, Anne M Johnson, Jessica A Kahn, Kimberley Kavanagh, Susanne K Kjaer, Erich V Kliewer, Philippe Lemieux-Mellouki, Lauri Markowitz, Aminata Mboup, David Mesher, Linda Niccolai, Jeannie Oliphant, Kevin G Pollock, Kate Soldan, Pam Sonnenberg, Sepehr N Tabrizi, Clare Tanton, Marc Brisson

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.